Study identifier:SH-NEN-0006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) versus Ranitidine 150mg bid for the Healing of NSAID-Associated Gastric Ulcers when daily NSAID use is continued
NSAID associated Gastric Ulcers
Phase 3
No
Esomeprazole, Ranitidine
Unmapped
400
Interventional
18 Years +
Allocation: None
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the treatment of these gastric ulcers with one of the three following treatment groups: esomeprazole 40 mg once daily; esomeprazole 20 mg once daily; or ranitidine 150 mg twice daily.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 20mg Oral tablet daily | Drug: Esomeprazole 20mg Oral tablet once daily Other Name: Nexium |
Experimental: 2 40mg oral tablet daily | Drug: Esomeprazole 40mg oral tablet once daily Other Name: Nexium |
Active Comparator: 3 150mg oral twice daily | Drug: Ranitidine 150mg oral twice daily Other Name: Zantac |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.